Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025


Crinetics announced new data from its clinical development program evaluating once-daily, oral investigational PALSONIFYTM (paltusotine) in acromegaly at ENDO 2025.

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025


Crinetics management will host a conference call at 4:30 p.m. ET to discuss Q2 2025 financial results and provide a business update.

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an aggregate of 77,875 restricted stock unit awards to 46 new non-executive employees.

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline


Crinetics announced eight abstracts from its novel clinical development programs will be presented at the Endocrine Society’s Annual Meeting, ENDO 2025, July 12-15, 2025, in San Francisco, California.

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025


Crinetics Pharmaceuticals will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025, from 9:00 AM to 12:00 PM ET.